Adagene Inc. (ADAG)
Market Cap | 131.91M |
Revenue (ttm) | 18.11M |
Net Income (ttm) | -18.95M |
Shares Out | 44.12M |
EPS (ttm) | -0.44 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,102 |
Open | 2.990 |
Previous Close | 3.040 |
Day's Range | 2.990 - 2.990 |
52-Week Range | 1.100 - 4.380 |
Beta | 0.62 |
Analysts | Strong Buy |
Price Target | n/a |
Earnings Date | Aug 29, 2024 |
About ADAG
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking... [Read more]
Financial Performance
In 2023, Adagene's revenue was $18.11 million, an increase of 94.90% compared to the previous year's $9.29 million. Losses were -$18.95 million, -76.31% less than in 2022.
Financial StatementsNews
![](https://cdn.snapi.dev/images/v1/n/k/conf1-2444436.jpg)
Adagene to Present at Investor Conferences in June
SAN DIEGO and SUZHOU, China, May 22, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today ann...
![](https://cdn.snapi.dev/images/v1/a/h/press1-2348045.jpg)
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update
- Data for masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) highlight best-in-class therapeutic index and demonstrate clinical benefits in metastatic microsatellite-stable (MSS) colorectal cancer (CRC...
![](https://cdn.snapi.dev/images/v1/u/r/press14-2314136.jpg)
Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board
- Global oncology expert brings deep insight in colorectal cancer and role of CTLA-4 therapy as a cornerstone for combination immunotherapy -
![](https://cdn.snapi.dev/images/v1/q/k/conf5-2295589.jpg)
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024
SAN DIEGO and SUZHOU, China, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today an...
![](https://cdn.snapi.dev/images/v1/g/e/press6-2268953.jpg)
Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
- Interim data from additional MSS CRC patients dosed at 10 mg/kg every three weeks (Q3W) in combination with pembrolizumab anticipated in 2024 at a medical conference -
![](https://cdn.snapi.dev/images/v1/o/n/press17-2231588.jpg)
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
- Data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks (Q3W) in dose expansion showed clinical benefit including confirmed responses at higher, more frequent and ...
![](https://cdn.snapi.dev/images/v1/d/v/conf13-2215847.jpg)
Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium
- Interim results in MSS CRC suggest that SAFEbody precision masking technology enables a new standard for anti-CTLA-4 therapy at higher, more frequent and repeat doses by overcoming longtime safety-l...
![](https://cdn.snapi.dev/images/v1/t/c/press6-2139435.jpg)
Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023
- MSS CRC case examples reinforce optimal dosing regimen in ongoing phase 2 dose expansion, with a confirmed partial response at ADG126 10 mg/kg every three weeks plus pembrolizumab –
![](https://cdn.snapi.dev/images/v1/a/7/press5-2100451.jpg)
Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
- Data reinforces mechanism of action and selection of 10 mg/kg every three weeks repeat dosing regimen with pembrolizumab in ongoing MSS CRC dose expansion cohort –
![](https://cdn.snapi.dev/images/v1/d/g/conf16-2053055.jpg)
Adagene to Present at Investor and Scientific Conferences in September
– Adagene's CEO, Dr. Peter Luo, participating in SITC webinar on September 22 focused on essential role of Treg depletion for anti-CTLA-4 therapies –
![](https://cdn.snapi.dev/images/v1/z/a/press16-2044535.jpg)
Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update
- Best-in-class anti-CTLA-4 candidates designed for more than 30-fold increase in therapeutic index, addressing patient populations where CTLA-4-mediated Treg depletion is essential for efficacy –
![](https://cdn.snapi.dev/images/v1/v/g/press15-1871521.jpg)
Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate
SAN DIEGO and SUZHOU, China, May 04, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and developmen...
![](https://cdn.snapi.dev/images/v1/g/z/press5-1860283.jpg)
Adagene Announces Updates to its Board of Directors
SAN DIEGO and SUZHOU, China, April 28, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and developm...
![](https://cdn.snapi.dev/images/v1/d/e/press17-1841513.jpg)
Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors
- Results of dose escalation portion from phase 1b/2 trials of ADG126 in combination with anti-PD-1 therapies, including confirmed clinical responses, pave way for dose expansion in specific tumors -
![](https://cdn.snapi.dev/images/v1/b/r/press1-1816064.jpg)
Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update
- Clinical data for wholly-owned anti-CTLA-4 franchise show best-in-class safety profiles for unmasked and masked candidates, unlocking the full therapeutic benefit of anti-CTLA-4 in combination with...
![](https://cdn.snapi.dev/images/v1/n/g/press6-1797046.jpg)
Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April
- Clinical posters detail results of dose escalation portion of phase 1b/2 trials of ADG126 in combination with anti-PD-1 therapies, demonstrating benefits of SAFEbody precision masking technology -
![](https://cdn.snapi.dev/images/v1/b/r/press6-1782891.jpg)
Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory Board
- Brings deep insight in tumor-specific Treg depletion for anti-CTLA-4 therapies delivered intratumorally to overcome dose dependent toxicities -
![](https://cdn.snapi.dev/images/v1/v/r/press9-1700019.jpg)
Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-CTLA-4 SAFEbody® ADG126 up to 10 mg/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Phase 1b/2 Trial
- No dose-limiting toxicities observed when ADG126 combined up to 10 mg/kg with repeat cycles, highlighting compelling safety profile with SAFEbody precision masking technology -
![](https://cdn.snapi.dev/images/v1/v/t/conf10-1697483.jpg)
Adagene to Present at the Biotech Showcase™ 2023 in San Francisco on January 9
SAN DIEGO and SUZHOU, China, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announce...
![](https://cdn.snapi.dev/images/v1/c/b/press18-1678230.jpg)
Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody® ADG126 in Combination with Roche's Standard-of-Care for First-Line Advanced Liver Cancer
SAN DIEGO and SUZHOU, China, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announce...
![](https://cdn.snapi.dev/images/v1/c/x/press1-1646870.jpg)
Adagene Appoints Cuong Do to Board of Directors and Audit Committee
SAN DIEGO and SUZHOU, China, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announce...
![](https://cdn.snapi.dev/images/v1/k/k/press10-1630249.jpg)
Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors
- Interim phase 1b/2 data report safety profile of ADG116 across dosing levels, with repeat dosing of more than four cycles both as monotherapy and in combination with anti-PD-1 therapy -
![](https://cdn.snapi.dev/images/v1/1/j/press3-1578126.jpg)
Adagene Announces Poster Presentations on Anti-CTLA-4 NEObody™, ADG116, at Upcoming Society for Immunotherapy of Cancer's (SITC) Annual Meeting in November
- NEObody technology platform enables dynamic targeting of a distinct epitope of CTLA-4 for enhanced safety and efficacy -
![](https://cdn.snapi.dev/images/v1/o/l/press18-1539060.jpg)
Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced Tumors
- Best-in-class profile demonstrated with repeat dosing across dose levels -
![](https://cdn.snapi.dev/images/v1/5/m/press5-1525233.jpg)
Adagene Reports Financial Results for the Six Months Ended June 30, 2022 and Provides Corporate Updates
– Topline data for anti-CTLA-4 antibody, ADG116, shows compelling clinical safety and complete and partial responses as both a single agent and in combination with anti-PD-1 therapy; results to be pre...